Fundamental Analysis of CONCERT PHARMACEUTICALS INC(NASDAQ:CNCE) stock

Fundamental Rating

Taking everything into account, CNCE scores 3 out of 10 in our fundamental rating. CNCE was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CNCE as it has an excellent financial health rating, but there are worries on the profitability. CNCE is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CNCE has reported negative net income.

CNCE had a negative operating cash flow in the past year.

CNCE had negative earnings in 4 of the past 5 years.

In the past 5 years CNCE reported 4 times negative operating cash flow.

1.2 Ratios

The profitability ratios for CNCE are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CNCE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CNCE has more shares outstanding

There is no outstanding debt for CNCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 0.66, we must say that CNCE is in the distress zone and has some risk of bankruptcy.

CNCE's Altman-Z score of 0.66 is in line compared to the rest of the industry. CNCE outperforms 58.93% of its industry peers.

There is no outstanding debt for CNCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	0.66

ROIC/WACCN/A

WACC9.05%

2.3 Liquidity

A Current Ratio of 9.03 indicates that CNCE has no problem at all paying its short term obligations.

CNCE has a better Current ratio (9.03) than 67.55% of its industry peers.

CNCE has a Quick Ratio of 9.03. This indicates that CNCE is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of CNCE (9.03) is better than 67.55% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	9.03
Quick Ratio	9.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CNCE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.12%.

The Revenue for CNCE has decreased by -99.87% in the past year. This is quite bad

Measured over the past years, CNCE shows a very strong growth in Revenue. The Revenue has been growing by 176.94% on average per year.

EPS 1Y (TTM)-62.12%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q25.64%

Revenue 1Y (TTM)-99.87%

Revenue growth 3Y45.85%

Revenue growth 5Y176.94%

Revenue growth Q2Q-98.53%

3.2 Future

The Earnings Per Share is expected to grow by 15.00% on average over the next years. This is quite good.

The Revenue is expected to grow by 42.40% on average over the next years. This is a very strong growth

EPS Next Y-22.75%

EPS Next 2Y-10.27%

EPS Next 3Y2.66%

EPS Next 5Y15%

Revenue Next Year-99.69%

Revenue Next 2Y-37.26%

Revenue Next 3Y-0.95%

Revenue Next 5Y42.4%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CNCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CNCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.27%

EPS Next 3Y2.66%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CNCE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CONCERT PHARMACEUTICALS INC

NASDAQ:CNCE (3/3/2023, 7:00:00 PM)

After market: 8.4 +0.03 (+0.36%)

8.37

+0.01 (+0.12%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap401.95M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	9.03
Quick Ratio	9.03
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-62.12%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-22.75%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-99.87%

Revenue growth 3Y45.85%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CONCERT PHARMACEUTICALS INC (CNCE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens